secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-013837
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma reports 2025 net loss of $8.8M ($0.78/sh); cash $7.7M; norovirus challenge study underway
--------------------------------------------------------------------------------

- Net loss $8.8M ($0.78/sh) vs $17.5M ($1.72/sh) in 2024; R&D spend down to $5.1M from $12.5M.
- Unrestricted cash $7.7M at Dec 31, 2025 vs $9.9M a year earlier; working capital $5.9M.
- Phase 1b norovirus challenge study of CDI-988 underway at Emory; first cohort evaluating GII.2 strain.
- CDI-988 is first oral antiviral candidate for norovirus; no approved treatments/vaccines exist; $60B global burden.
- Influenza CC-42344 Phase 2a completed; efficacy not reported due to trial conduct; plans for additional Phase 2a study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/0001493152-26-013837-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013837

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer